“Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s72, https://doi.org/10.25251/skin.4.supp.72.